Rankings
▼
Calendar
TNGX
Tango Therapeutics, Inc.
$2B
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$12M
+8.2% YoY
Gross Profit
$12M
100.0% margin
Operating Income
-$33M
-283.3% margin
Net Income
-$29M
-251.3% margin
EPS (Diluted)
$-0.27
QoQ Revenue Growth
-41.6%
Cash Flow
Operating Cash Flow
-$33M
Free Cash Flow
-$34M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$352M
Total Liabilities
$123M
Stockholders' Equity
$229M
Cash & Equivalents
$53M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$12M
$11M
+8.2%
Gross Profit
$12M
$10M
+14.7%
Operating Income
-$33M
-$26M
-28.3%
Net Income
-$29M
-$22M
-31.0%
Revenue Segments
License Revenue
$12M
51%
Collaboration Revenue
$12M
49%
← FY 2024
All Quarters
Q4 2024 →
TNGX Q3 2024 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena